Korea United Pharm Inc. announced on the 25th that it recently held a seminar for medical professionals in Ulaanbaatar to introduce its new product, 'Clavixin Duo Capsule', a combination of aspirin and clopidogrel, to the Mongolian market. The event was attended by about 50 local specialists in the field of cardiology and was co-hosted with its Mongolian partner, Tsakhiur Tumur. Both companies plan to actively introduce this combination drug to the market.

During the seminar, Professor Sung Min-soo from Gangnam Severance Hospital's Neurology Department presented the clinical validity, product characteristics, and domestic prescription data. Professor Sung explained the formulation advantages of the combination drug, as well as its effect on improving patient medication adherence (the advantage of integrated dosing convenience that can lead to continuous medication adherence).

Korea United Pharm Inc. is using this meeting as an opportunity to enhance local medical professionals' awareness and expand prescriptions. Additionally, the company plans to increase the impact of key products such as the influenza treatment Tamisel Capsule and the analgesic and anti-inflammatory Clanza S Soft Capsule in the Mongolian market, thereby gradually expanding its export scale.

Meanwhile, the Mongolian pharmaceutical import market was valued at USD 155.64 million (KRW 22.9 billion) as of 2022. It has been experiencing continuous growth in recent years, with South Korea being the second-largest supplier of pharmaceuticals to Mongolia, indicating active trade relations.

Popular News